Months before a new Idaho law will require health insurance companies to expand breast cancer screening coverage, the Idaho Department of Insurance is guiding insurers on how to prepare.

Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...